To avoid overtransfusion, rEPO administration may be useful and it has been recently reported to be effective in 70% of both primary and secondary AIHA patients with a median Hb increase of 2.4 mg/dL (range 2–83), independently of AIHA type and number of previous therapy lines [25]. The gene discussed is GSTM1; the disease is autoimmune hemolytic anemia.